Literature DB >> 23865964

IHH gene polymorphism among three horse breeds and its application for association test in horses with osteochondrosis.

T Zabek1, P Golonka, A Fornal, E Semik.   

Abstract

Genetic polymorphism of IHH gene were investigated in Angloarabian, Polish Coldblood and Polish Halfbred horses with the inclusion of a group of Polish Halfbreds affected by osteochondrosis. IHH is a good candidate gene for association study of developmental disorders mainly affecting skeleton development. DNA sequence spanning IHH gene annotated in the horse genome and its putative promoter were investigated using SANGER sequencing. Analysis of genetic variability at polymorphic sites in the IHH gene body and the promoter region confirmed genetic differences between warmblood and coldblood horse breeds. A test for allelic and genotypic association at particular SNP sites revealed no association with osteochondrosis in investigated group of Polish Halfbreds. It was concluded that participation of different warmblood breeds in pedigrees of Polish Halfbreds make it difficult to search for genetic variants being associated with this complex disorder in this breed. IHH gene polymorphism investigated among three different horse populations would be valuable for further studies on equine bone developmental disorders.
© 2013 The Authors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23865964     DOI: 10.1111/j.1601-5223.2013.02282.x

Source DB:  PubMed          Journal:  Hereditas        ISSN: 0018-0661            Impact factor:   3.271


  2 in total

1.  Age-dependent expression of osteochondrosis-related genes in equine leukocytes.

Authors:  L Mendoza; D Piquemal; J P Lejeune; L Vander Heyden; F Noguier; R Bruno; C Sandersen; D Serteyn
Journal:  Vet Rec Open       Date:  2015-03-24

2.  SNP discovery from transcriptome of the swimbladder of Takifugu rubripes.

Authors:  Jun Cui; Hongdi Wang; Shikai Liu; Lifu Zhu; Xuemei Qiu; Zhiqiang Jiang; Xiuli Wang; Zhanjiang Liu
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.